文献速递临床试验与 GCP

纤维蛋白原浓缩物与冷沉淀相比对心脏手术后血液成分输注的影响:FIBRES随机临床试验

Effect of Fibrinogen Concentrate vs Cryoprecipitate on Blood Component Transfusion After Cardiac Surgery: The FIBRES Randomized Clinical Trial.
PubMed 文献 · JAMA · 2019-01-01

FIBRES随机临床试验在11家加拿大医院纳入心脏手术后出现临床显著出血和低纤维蛋白原血症的成人患者,比较纤维蛋白原浓缩物(4 g)与冷沉淀(10单位)的效果。主要终点为体外循环后24小时内输注的血液成分总量,纤维蛋白原浓缩物组平均16.3单位(95%CI 14.9至17.8),冷沉淀组17.0单位(95%CI 15.6至18.6),比值0.96(单侧97.5%CI -∞至1.09;非劣效性P<.001)。结论认为纤维蛋白原浓缩物在24小时内输注血液成分数量方面非劣效于冷沉淀,可考虑用于心脏手术中获得性低纤维蛋白原血症的出血管理。

要点

  • 心脏手术后临床显著出血伴低纤维蛋白原血症患者中,纤维蛋白原浓缩物在24小时血液成分输注量方面非劣效于冷沉淀。
  • 纤维蛋白原浓缩物组平均24小时输注16.3单位,冷沉淀组17.0单位,比值0.96(单侧97.5%CI -∞至1.09)。
  • 纤维蛋白原浓缩物组血栓栓塞事件26例(7.0%),冷沉淀组35例(9.6%)。

核心结论

  • 在体外循环后发生临床显著出血和低纤维蛋白原血症的心脏手术患者中,纤维蛋白原浓缩物在24小时内输注血液成分数量方面非劣效于冷沉淀。
  • 作者认为,心脏手术中获得性低纤维蛋白原血症患者的出血管理可考虑使用纤维蛋白原浓缩物。

研究设计与样本

  • 随机临床试验,在11家加拿大医院进行,纳入心脏手术后出现临床显著出血和低纤维蛋白原血症的成人患者。
  • 招募时间为2017年2月10日至2018年11月1日,最终28天随访于2018年11月28日完成。
  • 干预为体外循环后24小时内每次医嘱剂量给予纤维蛋白原浓缩物(4 g;n=415)或冷沉淀(10单位;n=412)。
  • 827例随机化患者中,735例(纤维蛋白原浓缩物组372例,冷沉淀组363例)接受治疗并纳入主要分析。
  • 计划纳入1200例,在随机化827例后因中期分析达到非劣效性停止标准而提前终止。

主要发现

  • 主要分析人群的中位年龄为64岁(四分位距53-72),女性占30%,72%接受复杂手术,95%为中重度出血,治疗前纤维蛋白原水平为1.6 g/L(四分位距1.3-1.9)。
  • 体外循环后24小时平均同种异体输血量:纤维蛋白原浓缩物组16.3单位(95%CI 14.9至17.8),冷沉淀组17.0单位(95%CI 15.6至18.6),比值0.96(单侧97.5%CI -∞至1.09;非劣效性P<.001;双侧95%CI 0.84至1.09;优效性P=.50)。
  • 血栓栓塞事件:纤维蛋白原浓缩物组26例(7.0%),冷沉淀组35例(9.6%)。

关键数值与推荐

  • 非劣效性阈值:均值单位数比值<1.2。
  • 主要终点为体外循环后24小时内输注的血液成分(红细胞、血小板、血浆)数量。

临床怎么用

  • 作者认为,心脏手术中获得性低纤维蛋白原血症患者的出血管理可考虑使用纤维蛋白原浓缩物。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Excessive bleeding is a common complication of cardiac surgery. An important cause of bleeding is acquired hypofibrinogenemia (fibrinogen level <1.5-2.0 g/L), for which guidelines recommend fibrinogen replacement with cryoprecipitate or fibrinogen concentrate. The 2 products have important differences, but comparative clinical data are lacking. OBJECTIVE: To determine if fibrinogen concentrate is noninferior to cryoprecipitate for treatment of bleeding related to hypofibrinogenemia after cardiac surgery. DESIGN, SETTING, AND PARTICIPANTS: Randomized clinical trial at 11 Canadian hospitals enrolling adult patients experiencing clinically significant bleeding and hypofibrinogenemia after cardiac surgery (from February 10, 2017, to November 1, 2018). Final 28-day follow-up visit was completed on November 28, 2018. INTERVENTIONS: Fibrinogen concentrate (4 g; n = 415) or cryoprecipitate (10 units; n = 412) for each ordered dose within 24 hours after cardiopulmonary bypass. MAIN OUTCOMES AND MEASURES: Primary outcome was blood components (red blood cells, platelets, plasma) administered during 24 hours post bypass. A 2-sample, 1-sided test for the ratio of the mean number of units was conducted to evaluate noninferiority (threshold for noninferiority ratio, <1.2). RESULTS: Of 827 randomized patients, 735 (372 fibrinogen concentrate, 363 cryoprecipitate) were treated and included in the primary analysis (median age, 64 [interquartile range, 53-72] years; 30% women; 72% underwent complex operations; 95% moderate to severe bleeding; and pretreatment fibrinogen level, 1.6 [interquartile range, 1.3-1.9] g/L). The trial met the a priori stopping criterion for noninferiority at the interim analysis after 827 of planned 1200 patients were randomized. Mean 24-hour postbypass allogeneic transfusions were 16.3 (95% CI, 14.9 to 17.8) units in the fibrinogen concentrate group and 17.0 (95% CI, 15.6 to 18.6) units in the cryoprecipitate group (ratio, 0.96 [1-sided 97.5% CI, -∞ to 1.09; P < .001 for noninferiority] [2-sided 95% CI, 0.84 to 1.09; P = .50 for superiority]). Thromboembolic events occurred in 26 patients (7.0%) in the fibrinogen concentrate group and 35 patients (9.6%) in the cryoprecipitate group. CONCLUSIONS AND RELEVANCE: In patients undergoing cardiac surgery who develop clinically significant bleeding and hypofibrinogenemia after cardiopulmonary bypass, fibrinogen concentrate is noninferior to cryoprecipitate with regard to number of blood components transfused in a 24-hour period post bypass. Use of fibrinogen concentrate may be considered for management of bleeding in patients with acquired hypofibrinogenemia in cardiac surgery. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03037424.

来源:JAMA,查看原文。版权归原作者所有。

引用

  1. Callum J, Farkouh ME, Scales DC, et al. Effect of Fibrinogen Concentrate vs Cryoprecipitate on Blood Component Transfusion After Cardiac Surgery: The FIBRES Randomized Clinical Trial. JAMA. 2019. PMID: 31634905. doi:10.1001/jama.2019.17312

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。